75%Confidence
0Views
FDASource
2026-03-10Date
Summary
Slate Run Pharmaceuticals recalls Eptifibatide Injection for labeling error (bolus vs. infusion dosing), a Class III issue indicating lower health risk but potential for medication errors. This highlights quality control gaps in packaging and labeling processes.
Actionable: Review Slate Run's compliance history and consider if this signals broader operational deficiencies that could affect other products.
AI Confidence: 75%
Data Points
firmSlate Run Pharmaceuticals
classificationClass III
statusOngoing
distributionNationwide within the USA.
productEptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now